• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease

byMinjee Kim
August 25, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy.

2. The incidence of thrombocytopenia and anemia was more common in patients treated with ruxolitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Allogeneic stem-cell transplantation is a life-saving therapy for various hematologic conditions. However, chronic GVHD is a serious complication that impairs its success and patients’ quality of life. Although glucocorticoids are the standard treatment for GVHD, approximately 50% of patients become refractory or dependent. Ruxolitinib, a Janus kinase 1 and 2 (JAK1/2) inhibitor, has been shown to be effective for GVHD in retrospective clinical studies. As such, this study examined the efficacy of ruxolitinib in treating chronic glucocorticoid-refractory and glucocorticoid-dependent GVHD. The study determined ruxolitinib resulted in a higher overall responses rate and more symptom reduction than control therapy. The study was limited by the open-label study design, which was needed to accommodate the various control-therapy options. Nonetheless, the study’s results were significant as a ruxolitinib treatment showed significantly greater disease response and symptom reduction compared to the control therapies.

Clicker to read the study in NEJM

Relevant Reading: Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

In-Depth [randomized controlled trial]: This multi-center randomized open-label controlled trial enrolled 329 patients from 149 centers in 28 countries. Patients who were at least 12 years old, diagnosed with glucocorticoid-refractory or glucocorticoid-dependent GVHD, previously underwent allogeneic stem-cell transplantation, and had previously responded to JAK inhibitors for acute GVHD were included in the study. Patients were excluded if they had received two or more systemic therapies for chronic GVHD alongside glucocorticoids. Patients were randomized in a 1:1 ratio to receive either ruxolitinib or control therapy defined as second-line treatments such as extracorporeal photopheresis, mycophenolate mofetil, or ibrutinib, respectively. The primary endpoint is the overall response, which consists of complete and partial responses at week 24. Notably, 82 patients (49.7%) discontinued ruxolitinib, 122 (74.4%) discontinued control therapy, and 61 (37.2%) crossed over from control therapy to ruxolitinib. Ruxolitinib resulted in higher overall response at 24 weeks (82 patients, 49.7%) compared to the control therapy (42 patients, 25.6%) (odds ratio [OR], 2.99; 95% confidence interval [CI], 1.44 to 2.60; risk ratio [RR], 1.93; 95% CI, 1.44 to 2.60; P<0.001). Additionally, patients are given ruxolitinib had longer failure-free survival (median failure-free survival, >18.6 months) than those on control therapy (median failure-free survival, 5.7 months) (hazard ratio, 0.37; 95% CI, 0.27 to 0.51; P<0.001). The probability of failure-free survival at 6 months was also higher in the ruxolitinib group (74.9%; 95% CI, 67.5 to 80.9) than control (44.5%; 95% CI, 36.5 to 52.1). Ruxolitinib-treated patients experienced higher rates of thrombocytopenia (15.2% vs. 10.1%), anemia (12.7% vs. 7.6%), and neutropenia (8.5% vs. 3.8%) than those given control therapy. The study noted longer follow-up than used in the current study would be necessary to demonstrate the impact ruxolitinib has on survival. Overall, this trial provided robust evidence for ruxolitinib treatment in the management of chronic glucocorticoid-refractory GVHD.

RELATED REPORTS

Ruxolitinib results in improved repigmentation as compared to vehicle-control in nonsegmental vitiligo

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #Allogenic stem-cell transplant#randomized trialglucocorticoidglucocorticoid-dependentglucocorticoid-refractorygraft-versus-host disease (GVHD)gvhdJAK1/2 inhibitorRuxolitinibstem cell transplantation
Previous Post

#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy

Next Post

Prenatal exposure to combined maternal drinking and smoking significantly associated with the risk of stillbirth

RelatedReports

Afamelanotide plus UV-B phototherapy effective for vitiligo
Chronic Disease

Ruxolitinib results in improved repigmentation as compared to vehicle-control in nonsegmental vitiligo

October 21, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

August 11, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

April 26, 2022
Next Post
Smoking associated with increased mortality in breast cancer patients

Prenatal exposure to combined maternal drinking and smoking significantly associated with the risk of stillbirth

Novel coronavirus identified from patients with pneumonia in Wuhan, China

COVID-19 infection associated with increased risk for acute myocardial infarction and ischemic stroke

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

22q11.22 status is a predictor of the degree of negative outcomes of IKZF1 alteration in pediatric B-cell acute lymphoblastic leukemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options